No Data
Tracking of Hong Kong stock concepts | The Medical Insurance Bureau has announced the new medical insurance catalog. Institutions believe that the golden opportunity to increase the allocation of the pharmaceutical sector has already opened (including con
The National Medical Insurance Bureau has conducted preliminary reviews on 440 pharmaceuticals for this year's medical insurance catalog, which is an increase from last year.
SSY Group Gets Drug Production, Registration Approvals for Parkinson's, Depression Drug in China
SSY Group (02005.HK): Entacapone/Levodopa and Fluvoxamine Maleate tablets (II) have obtained the pharmaceutical production registration certificate.
On August 7th, GeLongHui reported that SSY Group (02005.HK) announced that the group has obtained drug production registration approvals from the China National Medical Products Administration (NMPA) for entacapone/levodopa/carbidopa tablets (II) (entacapone 200mg, levodopa 100mg, carbidopa 25mg) and fluvoxamine maleate tablets (100mg), which belong to the fourth category of chemical drugs and are considered to have passed consistency evaluation. Among them, entacapone/levodopa/carbidopa tablets (II) is the first to be approved by a domestic enterprise. Entacapone/levodopa/carbidopa tablets (II) are mainly used for levodopa/decarboxylase
Express News | SSY Group - Obtained Approvals From Nmpa of China
Express News | SSY Group - Got Approvals for Drug Production and Registration for Entacapone, Levodopa and Carbidopa Tablets, Fluvoxamine Maleate Tablets
CICC: The pharmaceutical sector has entered a value investment range, focusing on the domestic innovative drug industry chain and going overseas.
China International Capital Corporation released a research report stating that after three years of systematic adjustment, the pharmaceutical sector has entered the range of value investment.
Earnings Are Growing at SSY Group (HKG:2005) but Shareholders Still Don't Like Its ProspectsNo Data
